



**Fig. 1.** Left: pneumothorax in right hemithorax. Right: pneumothorax resolved after chronic drainage.

The thoracic location of postherpetic neuralgia, in most cases, and the emergence of new techniques for pain control can lead to complications not initially considered, such as the case of our patient who presented pneumothorax in a healthy lung. The management of these cases begins with clinical suspicion, particularly in patients with risk factors. Treatment depends on the size of the pneumothorax. In the case of our patient, inter-procedural hemodynamic changes required urgent placement of a chest tube.

Despite their low incidence, facilities for the diagnosis and treatment of these complications must be available in these units, in the event that they do occur.

## References

- Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJM, Stalman WAB, van Essen GA. Herpes zoster and postherpetic neuralgia: Incidence and risk indicators using a general practice research database. *Fam Pract.* 2002;19:471–5.
- Helgason S, Peturson G. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. *BMJ.* 2000;321:794–6.
- Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. *Mayo Clin Proc.* 2009;84:274–80.
- Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. *Neurobiol Dis.* 1998;5:209–27.
- Mondelli M, Romano C, Della Porta P, Rossi A. Electrophysiological findings in peripheral fibres of subjects with and without post-herpetic neuralgia. *Electroencephalogr Clin Neurophysiol.* 1996;101:185–91.
- Schmid T, Pautex S, Lang PO. Acute and postherpetic neuralgia in the elderly: analysis of evidence for therapeutic options. *Rev Med Suisse.* 2012;8:1374–8, 1380–2.
- Khadem T, Stevens V. Therapeutic options for the treatment of postherpetic neuralgia: a systematic review. *J Pain Palliat Care Pharmacother.* 2013;27:268–83.
- Goßrau G. Postherpetic neuralgia. *Hautarzt.* 2014;65:461–70.
- Ke M, Yinghui F, Yi J, Xuehua H, Xiaoming L, Zhijun C, et al. Efficacy of pulsed radiofrequency in the treatment of thoracic postherpetic neuralgia from the angulus costae: a randomized, double-blinded, controlled trial. *Pain Phys.* 2013;16:15–25.
- Bonezzi C, Demartini L. Treatment options in postherpetic neuralgia. *Acta Neurol Scand Suppl.* 1999;173:25–35, discusión 48–52.
- Rahman M, Richter EO, Osawa S, Rhoton AL Jr. Anatomic study of the infraorbital foramen for radiofrequency neurotomy of the infraorbital nerve. *Neurosurgery.* 2009;64:423–7.
- Moore DC, Bridenbaugh DL. Pneumothorax: its incidence following intercostal nerve block. *JAMA.* 1962;182:1005–8.

Eva Cabrera César,\* M<sup>a</sup> Carmen Fernández Aguirre,  
M<sup>a</sup> Carmen Vera Sánchez, Jose Luis Velasco Garrido

*Servicio de Neumología, Hospital Universitario Virgen de la Victoria, Málaga, Spain*

\* Corresponding author.

*E-mail address:* [evacabrerasesar@gmail.com](mailto:evacabrerasesar@gmail.com) (E. Cabrera César).

1579-2129/

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Effect of Isoniazid Resistance on the Tuberculosis Treatment Outcome



### *Efecto de la resistencia a la isoniazida en el resultado del tratamiento de la tuberculosis*

Dear Director,

Tuberculosis (TB) remains a serious public health problem, and about one-third of world's population has active or latent TB. In Europe, there are 49 new cases and 7 deaths from TB every hour.<sup>1</sup> In Portugal, the incidence has been decreasing in recent years, and in 2014 the annual incidence was 20/1,00,000.<sup>2</sup>

Drug-resistant *Mycobacterium tuberculosis* has become a major threat to the control of TB and, among all first-line drugs, resistance is greatest to isoniazid (INH).<sup>3,4</sup> In Portugal, INH resistance was 10.5% in 2014 among TB cases in whom susceptibility testing was performed.<sup>2</sup> In fact, there has been an increasing resistance to INH, despite the decreasing number of TB cases.<sup>2</sup>

INH is a first-line anti-TB drug because of its potent early bactericidal activity against rapidly dividing cells.<sup>3,5</sup> However, treatment of active TB requires multiple anti-TB drugs along with INH to prevent selection and emergence of a drug-resistant population of *M. tuberculosis*. According to current World Health Organization (WHO) recommendations, INH mono-resistant TB should be treated with 6–9 months of rifampicin, ethambutol, and pyrazinamide, plus or minus a fluoroquinolone.<sup>6</sup> These are also the current treatment guidelines in Portugal.

TB is a notifiable disease in Portugal, so clinicians report all cases to National-Tuberculosis-Surveillance-System (SVIG-TB) that has data on patient demographics, comorbidities, risk behaviors, and clinical, radiological, and microbiological information, as well as treatment outcomes.<sup>7</sup>

The objectives of this study were identify factors associated with INH mono-resistance, compare treatment outcomes of INH mono-resistant patients with drug-susceptible patients and understand the causes of unsuccessful treatment among INH mono-resistance TB cases.

**Table 1**  
Demographic and clinical characteristics of enrolled TB patients.

Variable	Total (n = 7345)	INH mono-resistant (n = 242)	Drug-susceptible (n = 7103)	p-Value
Male	5013 (68%)	160 (66%)	4853 (68%)	0.512
Age (years), median (IQR)	44 (24)	44 (24)	44 (23)	0.713
<i>Country of origin</i>				
Portugal	6099 (83%)	191 (79%)	5908 (83%)	
Other country	1246 (17%)	51 (21%)	1195 (17%)	0.100
HIV positive	796 (11%)	18 (7%)	778 (11%)	0.104
Alcohol use	1077 (15%)	36 (15%)	1041 (15%)	1.000
IV-drug use	535 (8%)	11 (8%)	524 (8%)	0.116
Other drug use	655 (9%)	14 (6%)	641 (9%)	0.094
Correctional facility residence	130 (2%)	1 (0.4%)	129 (2%)	0.165
Homeless	134 (2%)	4 (2%)	130 (2%)	1.000
<i>Clinical history</i>				
Diabetes	479 (6%)	16 (7%)	463 (6%)	1.000
Silicosis	101 (1%)	2 (1%)	99 (1%)	0.642
Lung cancer	65 (1%)	0	65 (1%)	0.252
Other cancer	205 (3%)	7 (3%)	198 (3%)	1.000
Hepatic disease	334 (4%)	10 (4%)	324 (5%)	0.874
COPD	229 (3%)	3 (1%)	226 (3%)	0.128
<i>X-ray</i>				
Non-cavitary TB	2518 (40%)	84 (41%)	2434 (40%)	
Cavitary TB	3559 (57%)	114 (56%)	3485 (57%)	
Normal	159 (3%)	5 (3%)	154 (3%)	0.933
Pulmonary TB	6510 (89%)	210 (87%)	6300 (89%)	0.411
Other localization TB	835 (11%)	32 (13%)	803 (11%)	
Previous treatment	610 (8%)	17 (7%)	593 (8%)	0.538
Positive initial microscopy	4812 (69%)	154 (66%)	4658 (69%)	0.494
Positive initial culture	6819 (97%)	221 (97%)	6598 (97%)	1.000
Toxicity during treatment	158 (3%)	7 (3%)	151 (3%)	0.579
<i>Outcome</i>				
Successful (n = 7185)	6385 (89%)	210 (90%)	6175 (89%)	
Unsuccessful (n = 7185)	800 (11%)	24 (10%)	776 (11%)	0.743
Death (n = 7185)	461 (6%)	14 (6%)	447 (6%)	0.889
Treatment duration (days), median (IQR)	254 (104)	279 (94)	251 (104)	<0.001

TB: tuberculosis; INH: isoniazid; IQR: interquartile range; HIV: human immunodeficiency virus; IV: intravenous; COPD: chronic obstructive pulmonary disease.

To achieve the goals, data from Portuguese SVIG-TB were retrospectively analyzed from 1/January/2008 to 31/December/2014. INH mono-resistant cases were compared with drug-susceptible cases.

Culture-confirmed cases tested against first-line anti-TB drugs were included. INH mono-resistant TB cases were defined as having resistance to INH, but susceptibility to all other first-line anti-TB drugs. Drug-susceptible cases were those that had documented sensitivity to INH, rifampin, pyrazinamide, and ethambutol.

Susceptibility testing was carried out according to international standards; the method of proportions (liquid medium in the MGIT 960 system) was used to determine susceptibility to anti-tuberculosis drugs on: isoniazid (0.1 µg/ml), rifampicin (1 µg/ml), ethambutol (5 µg/ml), pyrazinamide (100 µg/ml) and streptomycin (1 µg/ml).

The WHO standard definitions were used for treatment outcomes.<sup>6</sup> Unsuccessful treatment includes failure, death during treatment and default. Cured patients and those with completed treatment were defined as treatment success. Cases with unknown outcomes (“in treatment” and “transferred”) were excluded.

Data were summarized by descriptive statistics, consisting of absolute (relative) frequencies or median (minimum–maximum), according to nature of variables.

Comparisons of demographic and clinical variables between two groups used the Chi-squared test (or Fisher's test, as appropriate) for categorical variables and the Mann–Whitney *U*-test for

continuous variables. A univariate analysis evaluated the effect of demographic characteristics and risk factors on treatment outcome for INH mono-resistance TB, through simple logistic regression.

Statistical analyses were performed with SPSS version 18.0 (PASW Statistic 18). Significance level was set at 0.05.

This study used surveillance data, with no possibility of linking patient records to patient personal data, so ethical approval was considered unnecessary.

Between 2008 and 2014, 18,429 TB cases were reported to SVIG-TB, from them 12,031 had culture confirmation and 10,588 of them were tested for sensitivity to first-line anti-TB drugs. According to drug susceptibility test, 7103 cases were susceptible to all first-line anti-TB drugs and 242 cases were INH mono-resistant. 3243 cases were excluded: 657 cases had resistance to rifampin and/or pyrazinamide and/or ethambutol and/or streptomycin, and 2061 had susceptibility to isoniazid and rifampin and no results for pyrazinamide, ethambutol and streptomycin.

Table 1 shows the characteristics of INH mono-resistant, drug-susceptible, and all eligible TB cases. In all groups, median patient age was 44 years, men were more likely to be cases than women, and most patients were born in Portugal. Most of studied clinical factors were not statistically different between INH mono-resistant and drug-susceptible groups. Although the two groups had no significant difference in treatment outcome and toxicity during treatment, the median treatment duration was longer in INH mono-resistant group (279 vs. 251 days,  $p < 0.001$ ).

**Table 2**  
Univariate analysis of the risk (odds ratio, OR) for unsuccessful treatment of TB patients with INH mono-resistant disease.

Variable	Successful (n = 210)	Unsuccessful (n = 22)	Unadjusted OR (95% CI)	p-Value
Age, median (IQR)	44 (23)	52 (43)	1.04 (1.01–1.06)	0.005
Sex				
Female	73 (35%)	7 (32%)	1.0	
Male	137 (65%)	15 (68%)	1.14 (0.45–2.93)	0.782
Alcohol use				
No	174 (86%)	14 (74%)	1.0	
Yes	29 (14%)	5 (26%)	2.14 (0.72–6.40)	0.172
IV-drug use				
No	198 (97%)	16 (80%)	1.0	
Yes	6 (3%)	4 (20%)	8.30 (2.11–32.27)	0.002
Other drug use				
No	194 (94%)	17 (90%)	1.0	
Yes	12 (6%)	2 (10%)	1.90 (0.39–9.21)	0.424
Homeless				
No	203 (99%)	19 (95%)	1.0	
Yes	2 (1%)	1 (5%)	5.34 (0.16–61.66)	0.179
HIV status				
Negative	198 (94%)	17 (77%)	1.0	
Positive	12 (6%)	5 (23%)	4.85 (1.53–15.40)	0.007
Previous TB treatment				
No	195 (93%)	21 (96%)	1.0	
Yes	15 (7%)	1 (4%)	0.62 (0.08–4.92)	0.650
Site of TB				
Extrapulmonary	27 (13%)	4 (18%)	1.0	
Pulmonary TB	183 (87%)	18 (83%)	0.66 (0.21–2.11)	0.488
Toxicity during treatment (n = 196)				
No	173 (98%)	16 (80%)	1.0	
Yes	3 (2%)	4 (20%)	14.42 (2.96–70.14)	0.001

TB: tuberculosis; INH: isoniazid; IQR: interquartile range; IV: intravenous; HIV: human immunodeficiency virus; TB: tuberculosis.

Several previous studies identified risk factors for INH mono-resistant TB, like previous TB treatment,<sup>5,8</sup> younger age,<sup>9,10</sup> foreign birth,<sup>10,11</sup> and various social factors.<sup>11</sup> However, as in Birmingham study,<sup>12</sup> no predictive factors for INH mono-resistant TB were found.

We did find that INH mono-resistant cases had a longer mean treatment duration, in agreement with some previous studies.<sup>5,8</sup> For example, a study in Georgia<sup>4</sup> reported that the extended length of regimen may be associated with reduce adherence. A study in San Francisco<sup>5</sup> suggested that new short-course treatment regimens are needed because of high incidence of drug toxicity. In contrast, a study in southern Mexico reported that treatment outcomes were similar for patients receiving a 6 month course and an extended course.<sup>13</sup>

In contrast to some studies,<sup>4,13,14</sup> but in agreement with San Francisco study,<sup>5</sup> we found no difference in the outcome of the two groups patients. This is in agreement with a previous report that INH mono-resistant treatment regimens have success rates of 95% or more.<sup>15</sup>

The treatment outcome of 232 INH mono-resistant cases were also analyzed (Table 2). Following the exclusion criteria, 10 of the INH mono-resistant cases without treatment results were excluded. The profile of these patients was similar to studied cases: median age was 46 years, 8 (80%) were male, 1 (10%) was HIV-positive, and 1 (12.5%) was an IV-drug user.

A univariate analysis showed that age (OR = 1.04; 95%CI = 1.01–1.06;  $p = 0.005$ ), intravenous (IV)-drug use (OR = 8.30; 95%CI = 2.11–32.27;  $p = 0.002$ ), HIV-positivity (OR = 4.85; 95%CI = 1.53–15.40;  $p = 0.007$ ) and toxicity during treatment (OR = 14.42; 95%CI = 2.96–70.14;  $p = 0.001$ ) were significantly associated with unsuccessful treatment outcome.

The Georgia study<sup>4</sup> reported treatment outcomes were worse for older patients among those who had INH mono-resistance. The Tanzania study<sup>14</sup> reported similar results, and also that HIV-infected individuals were more likely to experience unsuccessful treatment. The increased toxicity during treatment may be related to longer treatment duration, as described in San Francisco study.<sup>5</sup>

The main limitation of our study was the low number of unsuccessful treatments ( $n = 22$ ), which made multivariate analysis unfeasible.

Our findings reinforce the need for susceptibility testing and monitoring the treatment of INH mono-resistant cases, especially among the elderly, cases with HIV co-infection, IV drug users, and cases with toxicity during treatment.

### Acknowledgment

Rita Gaio was partially supported by CMUP (UID/MAT/00144/2013), which is funded by FCT (Portugal) with national (MEC) and European structural funds (FEDER), under the partnership agreement PT2020.

### References

1. World Health Organization. Global tuberculosis report 2015. Geneva: WHO Press; 2015.
2. Programa Nacional para a Infecção VIH/SIDA. Portugal infecção por VIH, SIDA e Tuberculose em números. Lisbon, Portugal: Direção-Geral da Saúde; 2015 [Portuguese].
3. Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect. 2015;21:59–68.

4. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007–2009. *Int J Tuberc Lung Dis*. 2012;16:812–6.
5. Chierakul N, Saengthongpinij V, Foongladda S. Clinical features and outcomes of isoniazid mono-resistant pulmonary tuberculosis. *J Med Assoc Thai*. 2014;97 Suppl. 3:S86–90.
6. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO Press; 2014.
7. Saúde D-Gd. Sistema de Vigilância da Tuberculose (SVIG-TB) - Substituição da aplicação informática e suporte do registo clínico dos casos N.º 6/D.T. In: Saúde Md, editor. Portugal: Direcção-Geral da Saúde, 2001. [consulted 17.03.17]: Available at: <https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/circular-normativa-n-6dt-de-13032001.aspx>. [Portuguese].
8. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-mono-resistant tuberculosis in the United States, 1993 to 2003. *Arch Intern Med*. 2008;168:1984–92.
9. Lai CC, Tan CK, Huang YT, Liao CH, Hsueh PR. Isoniazid-resistant tuberculosis, Taiwan, 2000–2010. *Emerg Infect Dis*. 2011;17:1769–70.
10. Forssbohm M, Loddenkemper R, Rieder HL. Isoniazid resistance among tuberculosis patients by birth cohort in Germany. *Int J Tuberc Lung Dis*. 2003;7:973–9.
11. Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, et al. Large outbreak of isoniazid-mono-resistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. *Euro Surveill*. 2011;16.
12. Munang ML, Kariuki M, Dedicoat M. Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999–2010. *QJM*. 2015;108:19–25.
13. Nagu TJ, Aboud S, Matee MI, Maeurer MJ, Fawzi WW, Mugusi F. Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. *J Antimicrob Chemother*. 2016. pii: dkw503.
14. Báez-Saldaña R, Delgado-Sánchez G, García-García L, Cruz-Hervert LP, Montesinos-Castillo M, Ferreyra-Reyes L, et al. Isoniazid mono-resistant tuberculosis: impact on treatment outcome and survival of pulmonary tuberculosis patients in southern Mexico 1995–2010. *PLoS One*. 2016;11:e0168955.
15. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med*. 2003;167:603–62.

Gisela Santos,<sup>a,\*</sup> Olena Oliveira,<sup>b</sup> Rita Gaio,<sup>c</sup> Raquel Duarte<sup>a,b,d</sup>

<sup>a</sup> Faculdade de Medicina, Universidade do Porto, Portugal

<sup>b</sup> EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Portugal

<sup>c</sup> Departamento de Matemática, Faculdade de Ciências da Universidade do Porto & Centro de Matemática da Universidade do Porto, Portugal

<sup>d</sup> Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal

Corresponding author.

E-mail address: [gisellammsantos@gmail.com](mailto:gisellammsantos@gmail.com) (G. Santos).

1579-2129/

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Pulmonary Actinomycosis in a Patient With Chronic Eosinophilic Pneumonia treated With Omalizumab<sup>☆</sup>



### Actinomicosis pulmonar en paciente con neumonía eosinófila crónica en tratamiento con omalizumab

To the Editor,

Pulmonary actinomycosis is a very rare diagnosis. It is a chronic, non-contagious, suppurative infection caused by microorganisms from the genus *Actinomyces*. These are Gram-positive, filamentous, branched bacilli.<sup>1</sup> The most common etiologic agent is *Actinomyces israelii*. Eight species have been identified as pathogenic in humans, one of which is *Actinomyces odontolyticus*, which very rarely causes lung infections. Pulmonary actinomycosis is mainly caused by the aspiration of these organisms from the oral cavity. We report the case of a patient with severe asthma and chronic eosinophilic pneumonia (CEP), with a diagnosis of pulmonary actinomycosis.

This was a 43-year-old man with severe asthma who had been admitted several times for pulmonary infiltrates that were classified as CEP (diagnosed from bronchoalveolar lavage [BAL] containing 52% eosinophils). He had been receiving oral corticosteroids for a year, but relapsed when the dose was reduced to 10 mg/day. Hyper eosinophilic syndrome was ruled out by blood tests. Treatment began with omalizumab to reduce the corticosteroid burden, given the patient's significant allergic component (IgE 1089 KU/l). Persistent peripheral eosinophilia (peak: 50.3% – 11 300 mm<sup>3</sup>) and repeatedly negative ANCA were observed in follow-up clinical laboratory tests. The patient responded well to omalizumab treatment, with no recurrence of asthma or pulmonary infiltrates, and the corticosteroids could be gradually tapered until they were discontinued.

Eighteen months after starting omalizumab and 12 months after discontinuing corticosteroid treatment, the patient consulted due to catarrh and dyspnea. Chest X-ray revealed pulmonary infiltrates and a small left pleural effusion. Of note on clinical laboratory tests was eosinophilia (38% – 3880 mm<sup>3</sup>). Bronchoscopy was performed, revealing mucosa with raised granular-like lesions, showing erythematous spots on a whitish base in the segments. Biopsies were obtained from these lesions (Fig. 1A). The biopsy specimens showed mucosa with squamous metaplasia and intense acute and chronic inflammatory infiltrate in the corium. The BAL cell count found 0% eosinophils. Another observation on bronchoscopy was the left segment 8 blocked by a very dense, whitish, stringy material, which was also biopsied (Fig. 1B). In view of these findings, a chest computed tomography was requested, which revealed an infiltrate in the left segment 8 (Fig. 1C), corresponding with the altered endoscopic image, a biopsy specimen of which subsequently grew *A. odontolyticus* on culture. The microorganism was identified using MALDI-TOF (matrix-assisted laser desorption/ionization) mass spectrometry, with a score of 1976. Given these results, treatment began with amoxicillin-clavulanic acid for 6 months, along with corticosteroids (1 mg/kg). The patient remained stable, without exacerbations and chest X-ray 2 months after admission showed resolution of the infiltrate.

Two months after completing the antibiotic treatment, the patient developed central chest tightness and dyspnea. Chest X-ray was performed, showing a new infiltrate in the left lower lobe. Bronchoscopy was repeated; the same lesions observed previously were present, and biopsies were obtained once again. On this occasion, the biopsy specimen showed intense, predominantly eosinophilic inflammation, and the BAL again showed 0% eosinophils. *A. odontolyticus* also grew on culture. A 1-month course of ceftriaxone was administered, followed by amoxicillin for 1 year. In view of eosinophils in blood (35% – 2860 mm<sup>3</sup>) and intense eosinophilic infiltrate in the bronchial biopsy, another cycle of corticosteroids was initiated. The patient's clinical progress was good, and he continues to be monitored in our clinic.

<sup>☆</sup> Please cite this article as: Erro Iribarren M, Cisneros Serrano C, Rajas Naranjo O, García Castillo E. Actinomicosis pulmonar en paciente con neumonía eosinófila crónica en tratamiento con omalizumab. *Arch Bronconeumol*. 2018;54:51–52.